Growth Metrics

bioAffinity Technologies (BIAF) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $9.3 million.

  • bioAffinity Technologies' Cash from Financing Activities rose 45815.4% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 33844.1%. This contributed to the annual value of $5.6 million for FY2024, which is 173126.38% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Cash from Financing Activities of $9.3 million as of Q3 2025, which was up 45815.4% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Cash from Financing Activities peaked at $15.0 million during Q3 2022, and registered a low of -$563556.0 during Q4 2022.
  • Over the past 4 years, bioAffinity Technologies' median Cash from Financing Activities value was $301363.0 (recorded in 2022), while the average stood at $2.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 12764.64% in 2023, then soared by 341207.98% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Cash from Financing Activities (Quarter) stood at -$563556.0 in 2022, then surged by 84.95% to -$84805.0 in 2023, then skyrocketed by 2488.86% to $2.0 million in 2024, then surged by 361.18% to $9.3 million in 2025.
  • Its Cash from Financing Activities was $9.3 million in Q3 2025, compared to $3.0 million in Q2 2025 and $1.0 million in Q1 2025.